ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
beti-cel gene therapy demonstrates durable efficacy in beta thalassaemia patients
June 18, 2021The betibeglogene autotemcel (beti-cel) gene therapy caused paediatric and adult beta thalassaemia patients to achieve transfusion independence lasting over two years. -
bluebird bio’s beta-thalassaemia gene therapy rejected by NICE
February 20, 2021bluebird bio’s beta-thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s National Institute of Health and Care Excellence (NICE) for use on the NHS.
Pharma Sources Insight January 2025
